Federica Cavallo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9369855/publications.pdf

Version: 2024-02-01

174	8,754	57631	49773
papers	citations	44 h-index	87 g-index

182	182	182	10431
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 1992, 70, 93-104.	13.5	1,348
2	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
3	2011: the immune hallmarks of cancer. Cancer Immunology, Immunotherapy, 2011, 60, 319-326.	2.0	316
4	Vaccines for tumour prevention. Nature Reviews Cancer, 2006, 6, 204-216.	12.8	312
5	Interleukin 12â€“mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. Journal of Experimental Medicine, 1998, 188, 589-596.	4.2	291
6	Zoledronic acid repolarizes tumourâ€associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	1.6	228
7	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. Journal of Experimental Medicine, 2001, 194, 1195-1206.	4.2	218
8	Cytokines, tumour-cell death and immunogenicity: a question of choice. Trends in Immunology, 1997, 18, 32-36.	7.5	161
9	Antitumor Efficacy of Adenocarcinoma Cells Engineered to Produce Interleukin 12 (IL-12) or Other Cytokines Compared With Exogenous IL-12. Journal of the National Cancer Institute, 1997, 89, 1049-1058.	3.0	158
10	IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. Journal of Immunology, 2001, 166, 3890-3899.	0.4	157
11	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. Cancer Research, 2004, 64, 2858-2864.	0.4	143
12	Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten. Cancer Research, 2010, 70, 2558-2567.	0.4	131
13	p130Cas as a New Regulator of Mammary Epithelial Cell Proliferation, Survival, and HER2-Neu Oncogeneâ€Dependent Breast Tumorigenesis. Cancer Research, 2006, 66, 4672-4680.	0.4	123
14	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
15	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Frontiers in Oncology, 2021, 11, 610303.	1.3	118
16	Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. European Journal of Immunology, 1995, 25, 1154-1162.	1.6	111
17	Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer. Gastroenterology, 2013, 144, 1098-1106.	0.6	104
18	Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. Cancer Research, 2016, 76, 62-72.	0.4	93

#	Article	IF	Citations
19	Inhibition of tumor growth and enhancement of metastasis after transfection of the Î³-interferon gene. International Journal of Cancer, 1993, 55, 320-329.	2.3	89
20	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. Cancer Research, 2004, 64, 4001-4009.	0.4	87
21	p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity. EMBO Journal, 2007, 26, 2843-2855.	3.5	83
22	State-of-the-Art Fusion-Finder Algorithms Sensitivity and Specificity. BioMed Research International, 2013, 2013, 1-6.	0.9	79
23	The noninflammatory role of high mobility group box 1/tollâ€like receptor 2 axis in the selfâ€renewal of mammary cancer stem cells. FASEB Journal, 2013, 27, 4731-4744.	0.2	78
24	A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9208-9213.	3.3	77
25	Vaccination for Treatment and Prevention of Cancer in Animal Models. Advances in Immunology, 2006, 90, 175-213.	1.1	75
26	SCA-1 Identifies the Tumor-Initiating Cells in Mammary Tumors of BALB-neuT Transgenic Mice. Neoplasia, 2008, 10, 1433-1443.	2.3	75
27	Immunosurveillance of Erbb2 Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance. Cancer Research, 2006, 66, 7734-7740.	0.4	73
28	The IKK/NF-Î°B signalingÂpathway requires Morgana to drive breast cancer metastasis. Nature Communications, 2017, 8, 1636.	5.8	73
29	Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice. Journal of Immunology, 2006, 177, 7626-7633.	0.4	71
30	Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale, 2015, 7, 6527-6533.	2.8	67
31	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. Clinical Cancer Research, 2014, 20, 3753-3762.	3.2	64
32	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. Journal of Clinical Investigation, 2004, 113, 709-717.	3.9	64
33	Cure of Mammary Carcinomas in Her-2 Transgenic Mice through Sequential Stimulation of Innate (Neoadjuvant Interleukin-12) and Adaptive (DNA Vaccine Electroporation) Immunity. Clinical Cancer Research, 2005, 11, 1941-1952.	3.2	62
34	In vivo evaluation of tumour acidosis for assessing the early metabolic response and onset of resistance to dichloroacetate by using magnetic resonance pH imaging. International Journal of Oncology, 2017, 51, 498-506.	1.4	57
35	State of art fusion-finder algorithms are suitable to detect transcription-induced chimeras in normal tissues?. BMC Bioinformatics, 2013, 14, S2.	1.2	56
36	Are oncoantigens suitable targets for anti-tumour therapy?. Nature Reviews Cancer, 2007, 7, 707-713.	12.8	55

#	Article	IF	Citations
37	A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. Cancer Research, 2010, 70, 2604-2612.	0.4	54
38	L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Oncotarget, 2016, 7, 66713-66727.	0.8	54
39	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs, 2021, 13, 1913791.	2.6	53
40	Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. European Journal of Immunology, 1996, 26, 1851-1859.	1.6	52
41	miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2. American Journal of Pathology, 2013, 182, 2058-2070.	1.9	52
42	CSPG4: a prototype oncoantigen for translational immunotherapy studies. Journal of Translational Medicine, 2017, 15, 151.	1.8	51
43	Novel insights into Notum and glypicans regulation in colorectal cancer. Oncotarget, 2015, 6, 41237-41257.	0.8	50
44	A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancerin vivo. OncoImmunology, 2018, 7, e1408746.	2.1	49
45	Breast cancer stem cell antigens as targets for immunotherapy. Seminars in Immunology, 2020, 47, 101386.	2.7	48
46	Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. International Journal of Cancer, 2005, 113, 67-77.	2.3	47
47	NK cells control breast cancer and related cancer stem cell hematological spread. OncoImmunology, 2017, 6, e1284718.	2.1	47
48	Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential. British Journal of Cancer, 2021, 124, 207-216.	2.9	44
49	Cancer immunoprevention. Future Oncology, 2005, 1, 57-66.	1.1	43
50	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. American Journal of Pathology, 2005, 166, 1205-1216.	1.9	43
51	Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines. Viruses, 2020, 12, 488.	1.5	43
52	Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene, 1997, 14, 1805-1810.	2.6	42
53	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. Cancer Immunology Research, 2015, 3, 1333-1343.	1.6	42
54	Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant <scp>CSPG4</scp>â€antigen electrovaccination. Veterinary and Comparative Oncology, 2017, 15, 996-1013.	0.8	42

#	Article	IF	Citations
55	ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas. Current Protocols in Immunology, 2008, 82, Unit 20.9.1-20.9-10.	3.6	41
56	RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear microRNA-dependent manner in single cells. Genome Biology, 2017, 18, 37.	3.8	40
57	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. Current Drug Targets, 2011, 12, 1957-1973.	1.0	39
58	Ultrasound-activated decafluoropentane-cored and chitosan-shelled nanodroplets for oxygen delivery to hypoxic cutaneous tissues. RSC Advances, 2014, 4, 38433-38441.	1.7	39
59	2H,3H-Decafluoropentane-Based Nanodroplets: New Perspectives for Oxygen Delivery to Hypoxic Cutaneous Tissues. PLoS ONE, 2015, 10, e0119769.	1.1	39
60	Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Research, 2007, 9, 211.	2.2	38
61	The Promise of Preventive Cancer Vaccines. Vaccines, 2015, 3, 467-489.	2.1	38
62	Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma. Veterinary Journal, 2011, 190, e26-e30.	0.6	37
63	Fighting breast cancer stem cells through the immune-targeting of the xCT cystineâ€“glutamate antiporter. Cancer Immunology, Immunotherapy, 2019, 68, 131-141.	2.0	37
64	Requirement for IFN-Î³, CD8+ T Lymphocytes, and NKT Cells in Talactoferrin-Induced Inhibition of neu+ Tumors. Cancer Research, 2007, 67, 6425-6432.	0.4	36
65	A plant-expressed conjugate vaccine breaks CD4⁺ tolerance and induces potent immunity against metastatic Her2⁺ breast cancer. OncoImmunology, 2016, 5, e1166323.	2.1	36
66	A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis, 2012, 15, 305-316.	3.7	35
67	DNA vaccination against oncoantigens. OncoImmunology, 2012, 1, 316-325.	2.1	34
68	The importance of comparative oncology in translational medicine. Cancer Immunology, Immunotherapy, 2015, 64, 137-148.	2.0	34
69	Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. Magnetic Resonance Imaging, 2015, 33, 725-736.	1.0	34
70	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1839-1853.	2.0	34
71	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 799.	1.8	33
72	Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Research, 2005, 65, 1071-8.	0.4	33

#	Article	IF	Citations
73	Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Antiâ€“neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice. Cancer Research, 2008, 68, 7530-7540.	0.4	32
74	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. Progress in Molecular Biology and Translational Science, 2019, 164, 119-188.	0.9	32
75	Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota. International Journal of Molecular Sciences, 2020, 21, 9418.	1.8	32
76	Recombinant human lactoferrin induces human and mouse dendritic cell maturationviaTollâ€like receptors 2 and 4. FASEB Journal, 2014, 28, 416-429.	0.2	31
77	Immunological inhibition of carcinogenesis. Cancer Immunology, Immunotherapy, 2004, 53, 204-216.	2.0	30
78	DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Therapy, 2008, 15, 108-114.	2.2	30
79	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. OncoImmunology, 2016, 5, e1253653.	2.1	30
80	Stat3 is required for anchorageâ€independent growth and metastasis but not for mammary tumor development downstream of the ErbBâ€2 oncogene. Molecular Carcinogenesis, 2010, 49, 114-120.	1.3	29
81	Murine pneumotropic virus chimeric Her2/neu virusâ€like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. International Journal of Cancer, 2009, 124, 150-156.	2.3	28
82	An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. BMC Bioinformatics, 2005, 6, S7.	1.2	27
83	Erbb2 DNA Vaccine Combined with Regulatory T Cell Deletion Enhances Antibody Response and Reveals Latent Low-Avidity T Cells: Potential and Limits of Its Therapeutic Efficacy. Journal of Immunology, 2010, 184, 6124-6132.	0.4	27
84	Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Frontiers in Oncology, 2013, 3, 122.	1.3	27
85	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. OncoImmunology, 2013, 2, e26137.	2.1	27
86	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Research, 2014, 16, R10.	2.2	27
87	A human papillomavirus 8 E7 protein produced in plants is able to trigger the mouse immune system and delay the development of skin lesions. Archives of Virology, 2011, 156, 587-595.	0.9	26
88	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nature Communications, 2017, 8, 14797.	5.8	26
89	Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer stem cells. OncoImmunology, 2018, 7, e1494108.	2.1	26
90	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. Cancer Immunology Research, 2020, 8, 1039-1053.	1.6	26

#	Article	IF	Citations
91	Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. Cancer Immunology Research, 2018, 6, 1417-1425.	1.6	25
92	Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. Cancers, 2020, 12, 1492.	1.7	25
93	Cytokine-Induced Tumor Immunogenicity: From Exogenous Cytokines to Gene Therapy. Journal of Immunotherapy, 1993, 14, 253-257.	1.2	24
94	Antibody-Dependent Natural Killer Cellâ€“Mediated Cytotoxicity Engendered by a Kinase-Inactive Human HER2 Adenovirus-Based Vaccination Mediates Resistance to Breast Tumors. Cancer Research, 2010, 70, 7431-7441.	0.4	24
95	Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients. Clinical Cancer Research, 2014, 20, 2910-2921.	3.2	24
96	Transduction of Genes Coding for a Histocompatibility (MHC) Antigen and for Its Physiological Inducer Interferon-Î³ in the Same Cell: Efficient MHC Expression and Inhibition of Tumor and Metastasis Growth. Human Gene Therapy, 1995, 6, 743-752.	1.4	23
97	DNA Vaccines Targeting Tumor Antigens to B7 Molecules on Antigen-Presenting Cells Induce Protective Antitumor Immunity and Delay Onset of HER-2/Neu-Driven Mammary Carcinoma. Clinical Cancer Research, 2008, 14, 6933-6943.	3.2	23
98	ErbB2 Receptor Over-Expression Improves Post-Traumatic Peripheral Nerve Regeneration in Adult Mice. PLoS ONE, 2013, 8, e56282.	1.1	23
99	Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. BioMed Research International, 2014, 2014, 1-16.	0.9	22
100	Angiomotin like-1 is a novel component of the N-cadherin complex affecting endothelial/pericyte interaction in normal and tumor angiogenesis. Scientific Reports, 2016, 6, 30622.	1.6	22
101	Protective Immunity Againstneu-Positive Carcinomas Elicited by Electroporation of Plasmids Encoding Decreasing Fragments of Rat Neu Extracellular Domain. Human Gene Therapy, 2008, 19, 229-240.	1.4	21
102	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers, 2011, 3, 3225-3241.	1.7	21
103	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. BMC Genomics, 2014, 15, S1.	1.2	20
104	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985549.	1.4	20
105	Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent ofHER-2/neuExpression. Journal of Immunology, 2006, 176, 7695-7703.	0.4	19
106	Attenuation of PI3K/Akt-Mediated Tumorigenic Signals through PTEN Activation by DNA Vaccine-Induced Anti-ErbB2 Antibodies. Journal of Immunology, 2010, 184, 4170-4177.	0.4	19
107	Axl-148b chimeric aptamers inhibit breast cancer and melanoma progression. International Journal of Biological Sciences, 2020, 16, 1238-1251.	2.6	19
108	Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. British Journal of Cancer, 1999, 79, 770-779.	2.9	18

#	Article	IF	Citations
109	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine, 2005, 23, 3280-3287.	1.7	17
110	Immunological prevention of spontaneous tumors: a new prospect?. Immunology Letters, 2002, 80, 75-79.	1.1	16
111	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. Journal of Immunology, 2014, 192, 5434-5441.	0.4	16
112	Xenogene vaccination in the therapy of cancer. Expert Opinion on Biological Therapy, 2014, 14, 1427-1442.	1.4	16
113	â€˜In Vitroâ€™, â€˜In Vivoâ€™ and â€˜In Silicoâ€™ Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector. Pharmaceutical Research, 2018, 35, 75.	1.7	16
114	Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies. Cells, 2021, 10, 108.	1.8	16
115	Targeting the Extracellular HSP90 Co-Chaperone Morgana Inhibits Cancer Cell Migration and Promotes Anticancer Immunity. Cancer Research, 2021, 81, 4794-4807.	0.4	16
116	Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. Journal of Translational Medicine, 2014, 12, 122.	1.8	15
117	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. Oncotarget, 2016, 7, 33081-33095.	0.8	15
118	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunology, Immunotherapy, 2005, 54, 599-610.	2.0	14
119	Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies. Leukemia, 2014, 28, 941-944.	3.3	14
120	Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?. Cancer Immunology, Immunotherapy, 2008, 57, 1685-1694.	2.0	13
121	Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice. Current Cancer Drug Targets, 2008, 8, 230-242.	0.8	13
122	Imaging DNA Damage Allows Detection of Preneoplasia in the BALB-neuT Model of Breast Cancer. Journal of Nuclear Medicine, 2014, 55, 2026-2031.	2.8	13
123	Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant <scp>CSPG4â€DNA</scp> electrovaccination: A retrospective study on 155 cases. Veterinary and Comparative Oncology, 2021, 19, 651-660.	0.8	13
124	The Amot/integrin protein complex transmits mechanical forces required for vascular expansion. Cell Reports, 2021, 36, 109616.	2.9	13
125	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by Î³-interferon transfectants through host lymphocytes. International Journal of Cancer, 1995, 61, 425-430.	2.3	12
126	Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Biochemical Pharmacology, 2011, 82, 1079-1089.	2.0	12

#	Article	IF	Citations
127	A Mathematical-Biological Joint Effort to Investigate the Tumor-Initiating Ability of Cancer Stem Cells. PLoS ONE, 2014, 9, e106193.	1.1	12
128	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. OncoImmunology, 2015, 4, e1005500.	2.1	12
129	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl-Î²-cyclodextrin complex and resveratrol suspension after oral administration. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2016, 86, 263-271.	0.9	12
130	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2⁺ mammary cancer. Plant Biotechnology Journal, 2016, 14, 153-159.	4.1	12
131	Cancer stem cell antigens as targets for new combined anti-cancer therapies. International Journal of Biochemistry and Cell Biology, 2020, 129, 105861.	1.2	12
132	Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. OncoImmunology, 2022, 11, .	2.1	12
133	Multi-level model for the investigation of oncoantigen-driven vaccination effect. BMC Bioinformatics, 2013, 14, S11.	1.2	11
134	Optical imaging detection of microscopic mammary cancer in ErbBâ€2 transgenic mice through the DA364 probe binding Î±_vÎ²₃ integrins. Contrast Media and Molecular Imaging, 2013, 8, 350-360.	0.4	11
135	Preclinical vaccines against mammary carcinoma. Expert Review of Vaccines, 2013, 12, 1449-1463.	2.0	11
136	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. Current Topics in Microbiology and Immunology, 2014, 405, 99-122.	0.7	10
137	Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. International Journal of Cancer, 2016, 139, 404-413.	2.3	9
138	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. OncoImmunology, 2016, 5, e1082705.	2.1	9
139	Evaluation of prognostic impact of preâ€treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant <scp>CSPG4</scp>â€antigen electrovaccination: anÂexplorativeÂstudy. Veterinary and Comparative Oncology, 2021, 19, 353-361.	0.8	9
140	Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and <scp>antiâ€CSPG4</scp> vaccination: A retrospective study on 68 cases (2010â€“2020). Veterinary and Comparative Oncology, 2022, 20, 189-197.	0.8	8
141	Toward a Long-Lasting Immune Prevention of HER2 Mammary Carcinomas: Directions from Transgenic Mice. Cell Cycle, 2004, 3, 702-704.	1.3	7
142	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
143	Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas. British Journal of Cancer, 2005, 93, 1250-1256.	2.9	6
144	Immunotherapy and immunoprevention of cancer: where do we stand?. Expert Opinion on Biological Therapy, 2005, 5, 717-726.	1.4	6

#	Article	IF	Citations
145	A DNA Vaccine against ERBB2 Impairs Chemical Carcinogenesis in Random-Bred Hamsters. Cancer Prevention Research, 2011, 4, 994-1001.	0.7	6
146	DNA vaccination against membrane-bound Kit ligand: A new approach to inhibiting tumour growth and angiogenesis. European Journal of Cancer, 2014, 50, 234-246.	1.3	6
147	Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns. Vaccines, 2017, 5, 20.	2.1	6
148	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. Cancers, 2021, 13, 894.	1.7	6
149	Strategies for cytokine utilisation in tumor therapy. Medical Oncology and Tumor Pharmacotherapy, 1993, 10, 53-59.	1.0	6
150	Genotypic, Phenotypic and Biological Characterization of a Novel Human Lung Adenocarcinoma Cell Line (LC 89). Oncology, 1994, 51, 220-223.	0.9	5
151	Liver-Specific siRNA-Mediated Stat3 or C3 Knockdown Improves the Outcome of Experimental Autoimmune Myocarditis. Molecular Therapy - Methods and Clinical Development, 2020, 18, 62-72.	1.8	5
152	IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells. Cancer Immunology, Immunotherapy, 2012, 61, 1473-1484.	2.0	4
153	Oncoantigens for an immune prevention of cancer. American Journal of Cancer Research, 2011, 1, 255-264.	1.4	4
154	Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy. Cells, 2022, 11, 172.	1.8	4
155	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. Frontiers in Veterinary Science, 2022, 9, 803093.	0.9	4
156	Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice. Cell Cycle, 2004, 3, 704-6.	1.3	4
157	Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?. Frontiers in Oncology, 2022, 12, 877384.	1.3	4
158	Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. Antiviral Research, 2016, 134, 182-191.	1.9	3
159	Abstract 2579: Combination with the novel tumor-targeted CEA-IL2v immunocytokine enhances the activity of ADCC-competent and glycoengineered antibodiesin vitroandin vivo. , 2014, , .		2
160	Targeting CD4+ CD25+ FOXP3+ Treg cells abrogates established mechanisms of immune tolerance, reshuffles the T cell repertoire and results in effective anti-tumor immunity. European Journal of Cancer, Supplement, 2008, 6, 167-168.	2.2	1
161	Digging in the RNA-seq Garbage: Evaluating the Characteristics of Unmapped RNA-seq Reads in Normal Tissues. , 2012, , .		1
162	Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth. OncoImmunology, 2014, 3, e27259.	2.1	1

#	Article	IF	Citations
163	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. Vaccines, 2020, 8, 166.	2.1	1
164	Cytokines and Tumor Immunogenicity. , 1998, , 231-247.		1
165	BALB-neuT Female Mice as a Dynamic Model of Mammary Cancer. , 2012, , 139-166.		1
166	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. Biomedicines, 2022, 10, 230.	1.4	1
167	From exogenous cytokines to gene therapy: Cytohine activated tumor inhibition.. Pharmacological Research, 1992, 26, 48-49.	3.1	0
168	Cancer stem cell based adjuvant for oncoantingen-driven vaccination. , 2011, , .		0
169	Abstract 1196: Identification of lung cancer associated oncoantigens as targets for active immunotherapy. , 2012, , .		0
170	A pipeline to detect antibody-targetable cancer stem cell proteins.. Journal of Clinical Oncology, 2012, 30, e13527-e13527.	0.8	0
171	Tumor Immunogenicity Induced by the Local Occurrence of Il-2. , 1993, , 31-37.		0
172	Abstract 3553: xCT is a new cancer stem cell immunotherapeutic target for breast cancer. , 2015, , .		0
173	Abstract 5572: AX09: an immunotherapy candidate targeting the breast cancer stem cell protein xCT. , 2017, , .		0
174	Canine Melanoma and Osteosarcoma Immunotherapy by Means of In Vivo DNA Electroporation. , 2021, , 277-304.		0